MC10 Inc., UCB Partner for Innovative Solutions for Patients with Neurological Disorders

MC10 Inc. and global biopharmaceutical company UCB announced that they have entered into a partnership to develop MC10’s Biostamp platform for patient-focused disease management solutions. The collaboration will evaluate the integration of MC10’s novel, conformal sensing platform with UCB’s pharmaceutical products to make a positive difference in the lives of people living with severe neurological disorders.

MC10 develops stretchable, electronic sensing systems that bend, flex and twist to match the properties of the human body. MC10’s Biostamp platform offers a unique, patient-friendly solution for disease monitoring and management. This passive monitoring of patient health data will not only help patients but also doctors to provide more personalized care. Additionally, it could help to accelerate neuroscience clinical research and provide insight into the real world impact of therapies.

“Wearable technology has the power to transform the way healthcare is both received and delivered,” said Ben Schlatka, co-founder and vice president of corporate development at MC10. “At MC10, we have recognized that the most exciting applications of our technology emerge through collaborations with industry-leading partners. UCB’s patient-centric approach to medicine was a great fit with MC10’s human-centric approach to wearable technology design. We look forward to working together to build an innovative solution for patients living with severe diseases.”

“At UCB, we are committed to transforming the lives of people living with severe diseases by finding innovative ways to provide patients with solutions to problems that medicines alone cannot address” said Michael Gold, vice president, head of CNS practice, of UCB. “That is why we are pleased and excited to team up with MC10, with the aim to help patients and their families enjoy more normal, everyday lives.”